Liver cancer is the sixth most common cancer in the world, but there has been almost no progress in new drug development. One of the factors restricting the drug development is the lack of preclinical animal models that accurately evaluate potential anticancer agents. Patient-Derived tumor Xenograft (PDX) model are based on the transfer of primary tumors directly from the patients into an immunodeficient mice. Because PDX mice are derived from human tumors, they offer a tool for developing anticancer therapies and personalized medicine for patients with cancer. In addition, these models can be used to study metastasis and tumor evolution. This database collected numerous liver cancer PDX models to provide comprehensively resources for liver cancer drug development. Table below showed the type of data in the database.
|DataSet1||46||40||Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) (raw data: GSE90563)||40||Affymetrix Genome-Wide Human SNP 6.0 Array (raw data: GSE90651)||21||ZhongShan
|DataSet2||65||43||Affymetrix Human Gene Expression Array (GPL15207)||42||Affymetrix Genome-Wide Human SNP 6.0 Array||0||WuXi AppTech||PMID: 26062443|